SEROTONIN TRANSPORTER TRIALLELIC GENOTYPE AND RESPONSE TO CITALOPRAM AND RISPERIDONE IN DEMENTIA WITH BEHAVIORAL SYMPTOMS

OBJECTIVE: The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics (SGAs) are poorly tolerated, and efficacy of alternative treatments, e.g. selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dombrovski, Alexandre Y., Mulsant, Benoit H., Ferrell, Robert E., Lotrich, Francis E., Rosen, Jules I., Lotz, Meredith, Houck, Patricia R., Mazumdar, Sati, Pollock, Bruce G.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2887732/
https://ncbi.nlm.nih.gov/pubmed/19996755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0b013e328333ee10
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars